Stock data

Mcap (SARmn)

Avg. Trd. Val (SARmn)

2330

9,971

23.6

88.2%

10.7%

0.40%

TASI ticker

Free Float

105

95

85

75

65

QFI Holding

TASI FF weight

Source: Bloomberg

Prices indexed to 100

Source: Bloomberg



Target Price: SAR48.0/share
Market price: SAR38.35/share

Upside: +25.2%
Rating: Overweight

Advanced Petrochemical Company - APPC

PDH-PP plant yet to be priced in; Remain Overweight

- PDH-PP expansion is on track (88% complete), which will more than double annual production and earnings next year; however, project costs surpass our earlier estimates.
- Despite weak spreads, we remain positive, due to i) industry-leading operating rates, ii)
 PDH-PP expansion (likely to start in 2H24), iii) significant earnings growth with healthy
 FCF generation from 2025, and iv) a possible resumption of dividends (likely in 2025).
- We revise our TP to SAR48.0/sh. (SAR54.0/sh. earlier) to reflect higher-than-expected PDH-PP expansion capex (+39% over initial estimate) and relatively lower spreads.

PDH-PP expansion acts as a key positive catalyst: The new PDH-PP plant is expected to be finally completed in 2H24 (slightly delayed from the earlier start-up timeline of 2Q24; source: 2023 board report). Post completion, APPC's PDH and PP capacity will expand by 843ktpa and 800ktpa, respectively, which will more than double the current capacities and top-line / bottomline (at full utilization rate). However, we note that the company has been witnessing a significant increase in capex over its planned capex, rising from SAR7bn earlier announced capex to possibly reach SAR9.8bn (+39% rise; based on capex spent so far and future capital commitments) with a possibility of further escalation. Despite a rise in capex spending, we still believe that the PDH-PP expansion will remain a key positive catalyst for the stock this year, given the continuous weak product spreads. As the project is near to completion (~88% work is done), we start factoring it in our forecasts (assumed the commercial production to begin in 4Q24 with revised capex assumptions). We expect the ramp-up period would be relatively faster, but the company may face initial start-up costs, higher depreciation, and financial expenses post commercialization, which may weigh on earnings later this year before realizing its full benefits in 2025. Overall, despite increased capex, we still see this expansion as an EPS accretive, which is not reflecting in current stock price, in our view.

Product spreads to remain stable, although below the historical levels: We expect the product spread to remain under check in 2024e with the PP-Propane spread likely to remain mostly stable at US\$424/mt before gradually improving to US\$459/mt in 2025e (although likely to remain below the historical average of US\$570/mt over 2018-23).

Kunal Doshi

Kunal.doshi@gibcapital.com

+966-11-834 8372

Figure 1: Key financial metrics							
SARmn	2022a	2023 a	2024 e	2025 e			
Revenue	2,948	2,374	2,827	5,623			
Revenue growth	-5%	-20%	19%	99%			
Gross Profit	536	447	520	1,114			
Gross Profit margin	18%	19%	18%	20%			
EBITDA	615	452	608	1,368			
Op. income	399	274	338	799			
Net profit	295	171	201	404			
Net profit margin	10%	7%	7%	7%			
EPS	1.1	0.7	0.8	1.6			
P/E	33.8x	58.0x	49.4x	24.6x			

Source: Company data, GIB Capital



Lower product spreads could be attributable to weak PP prices (averaged at \sim US\$990/mt in 1Q24 so far; +3% q/q; remain below the historical average) on excess supply and weak demand, coupled with relatively high Propane prices (1m lag - averaged at \sim US\$620/mt in 1Q24; +6% q/q; remain above the historical average). Nonetheless, we may expect a sustainable recovery in PP demand and prices later this year or early next year, aided by a recovery in demand on improvement in the global economy, and a possible recovery in China.

Advanced inks SAR717mn worth of EPC contract for isopropanol plant: APPC, last month, announced the signing of EPC contracts worth SAR717mn (US\$191.3mn) with SGC eTEC E&C and SGC Arabia Co. Ltd. for the construction of the isopropanol plant (70ktpa capacity) in Jubail Industrial City. The project is expected to be completed in 32 months and is likely to begin commercial production by 4Q26. We note that this project is part of its already-announced PDH-PP project, which is expected to begin during 2H24. Based on our quick calculations, the isopropanol plant may contribute "SAR80mn annually (assuming full capacity), which is "3% of 2023 revenue. However, we await further details before factoring it into our forecasts.

4Q23 earnings: Top-line dropped 3.9% q/q to SAR571mn, largely in line with our estimate of SAR594mn (consensus: SAR591mn). The q/q decline in revenue could be due to lower PP prices. Further, as expected, higher Propane price dragged gross margin down by 3.4ppts to 17.2% (GIBCe: 16.7%), resulting in a ~20% decline in gross profit (in-line). However, higher-than-expected OPEX (likely due to year-end adjustments; ~19% q/q) impacted operating profit. Nonetheless, a key takeaway from 4Q23 earnings is the improvement in losses from its JV, SK Advanced, which reported lower losses at SAR21mn compared to our estimate of SAR33mn (SAR45mn losses in 4Q22 and SAR32mn losses in 3Q23). Accordingly, better-than-expected equity losses helped the company to beat our earnings estimate. Overall, net income declined by ~49% q/q to reach SAR23mn, above our estimate of SAR19mn (consensus: SAR30mn).

Figure 2: 4Q23 results summary

SARmn	4Q23	4Q22	y/y %	3Q23	q/q %	GIBC est.	Variance %
Revenues	571	611	-6.5%	594	-3.9%	594	-3.9%
Cost of sales	473	544	-13.1%	472	0.2%	495	-4.4%
Gross profit	98	67	46.3%	122	-19.7%	99	-1.3%
Opex	50	37	35.1%	42	19.0%	45	10.6%
Operating profit	48	30	60.0%	80	-40.0%	54	-11.3%
Net income	23	(6)	NM	45	-48.9%	19	18.4%
Gross margin	17.2%	11.0%		20.5%		16.7%	
Operating margin	8.4%	4.9%		13.5%		9.1%	
Net margin	4.0%	-1.0%		7.6%		3.3%	

Source: Company data, GIB Capital

Valuation: Post including the new PDH-PP expansion project in our forecasts (earlier, we used to add its fair value separately), 1Q24 shutdown (23 days for PP and 28 days for PDH plants), and revised product spreads, we raise our 2024 top line by 14% upwards but cut earnings by 51%, mainly due to higher depreciation and financial charges post the expansion. We also assume higher capex (~SAR2.4bn) to factor in a rise in spending associated with the PDH-PP expansion projects, resulting in a negative FCF for 2024e. Nonetheless, for 2025e, we expect the top-line and bottom-line to grow 99% y/y and 101%, respectively, realizing the full benefits of expansion. Overall, we revise TP to SAR48.0/sh. (SAR54.0/sh. earlier) based on an equal blend of DCF (7.5% WACC, 2% terminal growth) and EV/EBITDA (13x on 2025e EBITDA), implying an Overweight rating with ~25% upside potential.



Risks to our view:

- **Dividend risk:** With current spreads, there is a possibility for a reduction in expected dividends as debt and rates have increased to fund the growth plan.
- **Expansion risks:** Delay in execution, and cost overruns of the new project are major risk factors.
- **High benchmark set:** Additionally, there is a risk for the newer plants not to match the current plant's efficiencies given the high bar set by the current plant. Notably, the results of its Korean investment have not been as attractive as the Saudi plant.
- Others: Investment bets taken such as the one in Tasnee may not pay off as expected or may weigh on sentiments of investors looking for APPC as a pure PP-P play.



Financials

Figure 1: Financial statement

Income statement	2022 a	2023 a	2024 e	2025 e
Revenue	2,948	2,374	2,827	5,623
revenue y/y	-5%	-20%	19%	99%
COGS	2,412	1,927	2,307	4,509
Gross Profit	536	447	520	1,114
Gross Profit margin	18%	19%	18%	20%
Operating expenses	137	173	183	315
Operating profit	399	274	338	799
Operating margin	14%	12%	12%	14%
Finance costs	1	3	84	395
Net income	295	171	201	404
Net margin	10%	7%	7%	7%
<i>y/y</i>	-64%	-42%	18%	101%
EPS	1.1	0.7	0.8	1.6
DPS	2.2	0.0	0.0	1.0
Payout	194%	0%	0%	64%
EBITDA	615	452	608	1,368
Net debt	2,958	6,166	8,103	7,637
Balance Sheet	2022 a	2023 a	2024e	2025e
Inventories	181	193	282	327
Trade Receivables	354	331	501	579
Prepayments and Other Current				
Assets	165	187	187	187
Cash and Equivalents	1,007	924	136	202
Total Current Assets	1,707	1,635	1,106	1,295
Intangible Assets	0	0	0	0
Property, Plant & Equipment	5,185	8,615	10,715	10,371
Total Non-Current Assets	6,532	9,835	11,876	11,571
Total Assets	8,238	11,470	12,982	12,866
Current Liabilities	2,158	590	714	772
Non-current Liabilities	2,212	7,078	8,228	7,828
Equity	3,618	3,605	3,815	3,988
Total Equity and Liabilities	8,238	11,470	12,982	12,866
BVPS	31.7	44.3	50.2	49.7
Cookflow	2022-	2022-	2024-	2025
Cashflow	2022a	2023a	2024e	2025e
Cashflow from Operations	460	211	433	950
Cashflow from Investing	-1,971	-3,210	-2,371	-225
Cashflow from Financing	2,274	2,916	1,150	-659
Total Cashflows Source: Company, GIB Capital	764	-83	-787	66

Source: Company, GIB Capital



Figure 2: Key ratios 2022a **Key ratios 2023**a **2024**e **2025**e **Profitability ratios** 2% RoA 4% 1% 3% RoE 8% 5% 5% 10% RoIC 5% 3% 3% 7% Sales/Assets 36% 21% 22% 44% Net margin 10% 7% 7% 7% **Liquidity ratios** Current Assets/ Current Liabilities 0.8 2.8 1.5 1.7 Debt to Total Equity 110% 197% 216% 197% Receivable Days 44 51 65 38 37 **Inventory Days** 27 45 26 Payable days 22 24 40 25 **Debt ratios** Net Debt/EBITDA 4.8 13.3 5.6 13.6 Debt/Assets 48% 62% 63% 61% **Valuation ratios** P/E 33.8 58.0 49.4 24.6 P/B 1.2 0.9 0.8 0.8 EV/EBITDA 26.8 36.4 27.1 12.0 Div. yield 5.7% 0.0% 0.0% 2.6%

Source: Company, GIB Capital



Disclaimer

This research report has been prepared by GIB Capital, Riyadh, Saudi Arabia. It has been prepared for the general use of GIB Capital's clients and may not be altered, redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of GIB Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by GIB Capital. The information contained was obtained from various public sources believed to be reliable, but we do not guarantee its accuracy. GIB Capital makes no representations or warranties (express or implied) regarding the data and information provided and GIB Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. GIB Capital or its officers (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. GIB Capital may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. GIB Capital and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document. Where the report contains or refers to a recommendation about a specific security or securities service, please note that it may not be suitable for all recipients. Please note that the achievement of any price target may be impeded by general market and economic trends and other external factors, or if a company's profits or operating performance exceed or fall short of our expectations. The subjectivity in future expectations is complex and may miss actual or reported numbers.

This research document and any recommendations contained are subject to change without prior notice. GIB Capital assumes no responsibility to update the information in this research document. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law, or which would subject GIB Capital to any registration or licensing requirement within such jurisdiction

The principal activities of GIB Capital are Dealing, Custody, Managing, Arranging and Advising pursuant to the Capital Market Authority ("CMA") License No. 07078-37.

We use a rating system based on potential upside, 1 year from today, based on our valuation models. For "Overweight" ratings, the estimated upside is >10%, for "Underweight", the estimated downside is <10%. For returns in between +/-10%. we have a Neutral rating.

Contact us for queries:

Sell Side Research Department, GIB Capital, B1, Granada Business & Residential Park, Eastern Ring Road, PO Box 89589, Riyadh 11692 www.gibcapital.com